Promising Results from clinical trial with ProTrans stem cells
NextCell Pharma AB ("NextCell") announces today that the primary efficacy measures have reached significance in the dose-escalation phase of the company’s clinical trial. After one year follow-up, the six patients treated with high- and medium-dose have retained their insulin production significantly better (P <0.01) as compared to the three patients who received a low-dose of the company's stem cell based drug candidate ProTrans. No serious side effects have been reported."The results very are promising, even though there are only few patients and this part of the clinical trial was an
The Säterinportti office campus in Leppävaara, Espoo, is the first ever property in Finland to have been awarded the international WELL Certificate. Säterinportti achieved the gold level of the WELL Core and Shell Certificate. WELL considers a building’s impact on the health and wellbeing of its users from seven different aspects. This is a rare occasion, as only a few individual properties in the Nordics have achieved the certification.At Säterinportti, significant investments have been made for the wellbeing of people working there, both in terms of comfort and building services. The
